- Home
- HRMY vs CSTM Comparison
HRMY vs CSTM Comparison
Compare HRMY & CSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- CSTM
- Stock Information
- Founded
- HRMY 2017
- CSTM 2010
- Country
- HRMY United States
- CSTM France
- Employees
- HRMY N/A
- CSTM N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- CSTM Metal Fabrications
- Sector
- HRMY Health Care
- CSTM Industrials
- Exchange
- HRMY Nasdaq
- CSTM Nasdaq
- Market Cap
- HRMY 2.1B
- CSTM 2.1B
- IPO Year
- HRMY 2020
- CSTM 2013
- Fundamental
- Price
- HRMY $32.29
- CSTM $14.98
- Analyst Decision
- HRMY Strong Buy
- CSTM Buy
- Analyst Count
- HRMY 9
- CSTM 3
- Target Price
- HRMY $55.33
- CSTM $18.00
- AVG Volume (30 Days)
- HRMY 678.1K
- CSTM 1.1M
- Earning Date
- HRMY 10-28-2025
- CSTM 10-22-2025
- Dividend Yield
- HRMY N/A
- CSTM N/A
- EPS Growth
- HRMY 58.41
- CSTM N/A
- EPS
- HRMY 3.10
- CSTM 0.22
- Revenue
- HRMY $772,527,000.00
- CSTM $7,605,000,000.00
- Revenue This Year
- HRMY $20.09
- CSTM $7.84
- Revenue Next Year
- HRMY $16.86
- CSTM $5.65
- P/E Ratio
- HRMY $10.42
- CSTM $68.69
- Revenue Growth
- HRMY 17.74
- CSTM 2.04
- 52 Week Low
- HRMY $26.47
- CSTM $7.33
- 52 Week High
- HRMY $41.61
- CSTM $17.27
- Technical
- Relative Strength Index (RSI)
- HRMY 30.41
- CSTM 57.45
- Support Level
- HRMY $31.61
- CSTM $13.60
- Resistance Level
- HRMY $37.05
- CSTM $15.36
- Average True Range (ATR)
- HRMY 1.18
- CSTM 0.46
- MACD
- HRMY -0.59
- CSTM 0.07
- Stochastic Oscillator
- HRMY 10.19
- CSTM 78.37
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About CSTM Constellium SE (France)
Constellium SE is engaged in the design and manufacture of rolled and extruded aluminium products, serving the packaging, aerospace, automotive, defence and other transportation and industry end-markets. The business is organized into three operating segments: the Packaging and Automotive Rolled Products segment which includes the production of rolled aluminium sheet products in European and North American facilities; the Aerospace and Transportation segment includes the production of rolled aluminium products and very limited volumes of extruded products in European and North American facilities; the Automotive Structures and Industry segment includes the production of extruded aluminium products and aluminium structural components.